Medicines of Tomorrow: Horizon Scanning Forum
![](https://healthcarelink-cpd-upload-files.s3.ap-southeast-2.amazonaws.com/images/8/e/3/8e3bb6b8880d6787b1ea983fc7d9d108.jpg)
![](https://healthcarelink-cpd-upload-files.s3.ap-southeast-2.amazonaws.com/images/thumbs/0/e/a/0ea8bcb2262187b9ce860fb94cd05a83.png)
Presented by Medicines Australia in partnership with the Australian Commonwealth Department of Health and Aged Care, Medicines of Tomorrow showcases the major global therapeutic advances delivering a step change in patient treatments and outcomes and disrupting our health care system in coming years.
Robust horizon scanning is an indicator of a world-class health system and insights through horizon scanning can speed up patient access to new medicines and improve health, wellbeing and economic outcomes.
This event serves as an important platform to showcase major therapeutic advances which may enter Australia’s regulatory or reimbursement systems within the decade and may represent a significant disruption in the treatment paradigm and/or require innovation in health care system planning. The Forum also highlights the potential implications for governments from the introduction of these advances in terms of resources, systems and processes.
Medicines of Tomorrow 2024This year, we bring together experts across four therapeutic areas where innovative new classes of medicines and treatments are on the horizon for Australians: cell and gene therapies, vaccine technology, novel antimicrobial resistance therapies and digital technologies such as artificial intelligence that are impacting medicine discovery and development processes.
Cell and gene therapies are revolutionising medicine and holds great potential to transform patient outcomes. Healthcare systems and processes, including HTA, service delivery and funding approaches, must adapt to ensure that Australians will benefit from these new technologies in efficient, patient centric healthcare delivery models. The cost, data impediments and unclear reimbursement pathways for cell and gene therapies pose a significant challenge to our existing health technology assessment system.
Advanced vaccine technologies: In a new era of infectious disease, characterised by outbreaks of emerging, re-emerging and endemic pathogens, investment in preventing disease is critical to the health of people, our economy and the sustainability of our healthcare system. Key to this is ensuring that our regulatory and reimbursement processes are ready to efficiently evaluate and appropriately value innovation and new technologies to continue to attract research and investment to Australia.
Novel antimicrobial resistance (AMR) is one of the top global public health and development threats facing man kind. It is estimated bacterial AMR was responsible for 1.27 million deaths in 2019 and has contributed to 4.95 million deaths worldwide. This session will look at the challenge of AMR, potential regulatory and reimbursement reforms, and new antimicrobial therapies in development.
Digital technologies are revolutionising the global pharmaceutical industry, through the use of AI, big data analytics and machine learning in the development of biotherapeutic products, pharmaceuticals and vaccines. How these technologies are regulated, funded and provided to patients needs to be considered in the coming years.
Horizon Scanning Forum 2024 Agenda- 8:30am Registrations open
- 9:30am Welcome
Welcome & opening remarks Ms Liz de Somer, Chief Executive Officer, Medicines Australia
Address from Assistant Minister for Health The Hon Ged Kearney MP
The Horizon Scanning Scene Ms Penny Shakespeare, Deputy Secretary, Department of Health and Aged Care
The patient voice Ms Ann Single, The Patient Voice Initiative
- 10:00am Session 1: Emerging Disruptive Technologies – Cell and Gene Therapies
Cell and gene therapies – call for strategic coordination Dr Marguerite Evans-Galea AM (session facilitator) Director, Australia’s Cell and Gene Catalyst
Cell and gene therapies – opportunities on the horizon Prof John Rasko AO Head of Department, Cell & Molecular Therapies, Royal Prince Alfred Hospital
Chimeric Antigen Receptor (CAR) T therapy A/Prof Philip Thompson, Peter MacCallum Cancer Centre Barriers to patient access to cell and gene therapies Mr Warwick Shaw, Market Access, Johnson and Johnson Innovative Medicine CRISPR/ Cas9 gene editing therapy Mr Quentin Bracquart, Principal, IQVIA Management Consulting
- 10:50am Session panel Q&A Session speakers and Agnes Nsofwa (Executive Director, Australian Sickle Cell Advocacy Inc) and Ms Katrina Lapham (Director, Strategic Market Access and Policy, Biointelect)
- 11:20am Morning Tea
- 11:45am Session 2: Novel technologies to prevent communicable diseases
Technologies in the pipeline to prevent communicable diseases Ms Jennifer Herz (session facilitator), Co-Founder & Director, Biointelect
Emerging communicable threats and Australia’s preparedness Prof Paul Kelly, Chief Medical Officer, Department of Health and Aged Care
Challenges and opportunities to implement novel technologies to prevent communicable diseases Prof Paul Griffin, Director of Infectious Diseases at Mater Health Services Brisbane
Industry vaccines technology showcase presentations Dr Krishan Thiru, Medical Director, Pfizer Australia Dr Iris Depaz, Head of Medical Vaccines ANZ, Sanofi
- 12:35pm Panel Q&A Session speakers
- 1:00pm Lunch Break
- 1:45pm Session 3: Novel Antimicrobial Technology
Patient story Mr Chris Bond OAM PLY, Captain of the Australian Steelers Wheelchair Rugby team
The Antimicrobial (AMR) crisis Mr Andrew Bowskill (session facilitator) Director of Stakeholder Engagement for Queensland, MTPConnect. Co-chair Australian Antimicrobial Resistance Network (AAMRNet)
Antimicrobial Regulation and Reimbursement Ms Renae Beardmore, Managing Director, Evohealth
Antimicrobial resistance, the clinical experience, and Phage Therapy Prof Jon Iredell, Senior Staff Specialist, Infectious Diseases & Microbiology, Westmead Hospital
Industry antimicrobial technology showcase presentation Dr Scott Preiss, Medical Affairs Director, Vaccines, GSK
- 2:35pm Session panel Q&A Session speakers and Mr Mike Stephens (Director of Medicines Policy and Program at the National Aboriginal Community Controlled Health Organisation (NACCHO)
- 3:05pm Session 4: Digital Technology
Industry digital technology showcase presentation: The Use of AI-driven in vitro diagnostic (IVD) tools Dr Diana Zhang, Fulbright Scholar & 2023 NSW Young Woman of the Year Finalist Ms Oona Reardon, Director, Pulse Economics Consulting
The Transformative Potential of Digital Health Kim Smyth (session facilitator), General Manager, Investment, AndHealth
Panel Q&A Session speakers and Olivia Nassaris (CEO Parkinsons Australia) and Dean Whiting (CEO Pathology Technology Australia)
- 3:40pm Working afternoon tea
- 3:50pm Session 5: Gearing up for change – reforming the system and the role of horizon scanning
Facilitator: Liz de Somer, Medicines Australia CEO Dr Anna Lavelle AM, Medicines Australia Chair Urs Voegeli, Managing Director J&J Dr Paul Fennessey, horizon scanning expert
Wrap up and closing remarks DoHAC and Medicines Australia
- 4:30pm – 6:00pm Networking drinks
- Aboriginal Sign Language Forum 2024
- Posted By The University of Sydney
- Posted Date: 2024-08-22
- Location:online
- About this event Event lasts 5 hours 30 minutes Organised by the Centre for Disability Re...
- Autism Expo
- Posted By Living on The Spectrum
- Posted Date: 2024-08-20
- Location:Canley Vale NSW 2166
- Welcome to the Autism Expo Australia, a premier event dedicated to supporting individuals with autis...
- VIC Chapter meeting – Wednesday 7 August 2024
- Posted By Day Hospitals Australia
- Posted Date: 2024-07-19
- Location:online
- The next VIC Chapter Meeting will take place on Wednesday, 7 August 2024. The meeting will take pla...
- OT MENTAL HEALTH FORUM 2024 EMPOWERING MINDS TRANS...
- Posted By Occupational Therapy Australia
- Posted Date: 2024-07-11
- Location:online
- Melbourne Convention and Exhibition Centre Occupational Therapy Australia is pleased to present t...